Sutro Biopharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sutro Biopharma, Inc.
The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.
A year after COVID-19 first turned the world upside down, executives across the biopharma industry consider what 2021 holds in store. The impact of the pandemic will have profound and long-lasting implications for a sector that has been at the heart of responding to the global health challenge.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Public Company Edition: Lilly’s COVID-19 antibody partner AbCellera launched one of the biggest IPOs of 2020, bringing in $483m. Also, two more SPACs went public; Sinovac, Biocryst and Kura Oncology arranged large financings; and Viatris plans post-merger layoffs.
- Drug Discovery Tools
Drug Discovery Tools
- Molecular Diversity